Objetive: Malonyl CoA is an important regulator of fatty acid oxidation in the heart secondary to its ability to inhibit camitine palmitoyltransferase 1 (CFT 1). Malonyl CoA is produced from acetyl CoA in a reaction catalyzed by acetyl CoA carboxylase (ACC). In this study we determined if alterations in malonyl CoA regulation of fatty acid metabolism are involved in the increase in energy transduction seen following an increase in cardiac work. Methods: Anesthetized, (open-chest, domestic swine were subjected to a 30 min control period followed by a 30 min treatment period with either dobutamine (15 pg. kg-' . min-' i.v.> (n -6) or saline (n = 6).
Introduction
Increases in cardiac contractile function are accompanied by parallel increases in fatty acid oxidation to meet the extra ATP demand [ 11. However, the subcellular mechanisms responsible for the acceleration of fatty acid metabolism have not been completely delineated. It has recently been demonstrated that malonyl CoA production by acetyl CoA carboxylase (ACC) is an important step in the regulation of fatty acid oxidation ( Fig. 1) [2-41. Malonyl CoA inhibits camitine palmitoyltransferase 1 (CpTl), a key regulatory enzyme of fatty acid catabolism which catalyzes the conversion of fatty acyl-CoA to fatty acylcarnitine [$I. Thus, a decrease in malonyl CoA production by ACC may act as an important metabolic regulatory mechanism, releasing the inhibition on CPTl and increasing fatty acid uptake and subsequent oxidation during increased cardiac work.
A direct phosphorylation and inhibition of ACC with increased cardiac work is one potential mechanism that would be responsible for a reduction in malonyl CoA levels. Two isoforms of ACC have been identified in rat heart-a 265 kDa isoform (ACC-265) and a more predominant 280 kD isoform [4, 6, 7] . ACC activity mechanisms [4, 8] . An important kinase in this process is S-AMP-activated protein kinase (AMPK) which phosphorylates and inactivates ACC [9] . The role of ACC and/or AMPK in regulating malonyl CoA content in response to increased cardiac work has not been elucidated, nor have ACC and AMPK activities been reported in a large animal. Furthermore, although Awan and Saggerson [2] have suggested that epinephrine can increase fatty acid oxidation and inhibit ACC in isolated cardiac myocytes, the effects of a P-adrenergic agonist on ACC and AMFK in an intact heart or large animal have not been reported.
The purpose of this study was to identify the mechanism responsible for the increase in fatty acid uptake in swine myocardium during an infusion of the selective P-agonist, dobutamine. We hypothesized that dobutamine would cause a decrease in myocardial malonyl CoA levels.
Methods
Experiments were performed on 12 overnight-fasted male domestic swine (30-35 kg) in accordance with the Guide for the Care and Use of Laboratory Animals (NM publication No. 85-23) and the Institutional Animal Care and Use Committee at Syntex. Animals were initially sedated with 6 mg/kg of Telazol (teletamine + zolazepam) (i.m.1, followed by an i.v. bolus injection of pentobarbital (15 mg/kg) . A tracheotomy was performed and the animals were ventilated with room air supplemented with 100% oxygen via a Harvard Respirator to maintain blood gases in the normal range (PO, > 100 mmHg, pCO, (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) ) Anesthesia was maintained with a continuous infusion of pentobarbital(5 mg * kg-' . h-l).
The heart was exposed via a midline stemotomy as previously described [lo] . A 7F Milar Mikrotip dual-transducer was advanced into the left ventricle through the carotid artery for determination of left ventricular pressure. A cannula was inserted into the left atrium for microsphere injections to determine regional myocardial blood flow. A 22-gauge angiocatb was placed in the anterior interventricular vein to collect coronary venous blood samples for analysis of MVO, and glucose, free fatty acid (FFA), and lactate concentrations. The femoral artery and vein were cannulated for arterial blood withdrawal and administration of heparin and intralipid, respectively.
Protocol
The animals were divided into two groups (n = 6/group). Each group underwent an identical 30 min control period followed by a 30 min treatment period. During the treatment period, 6 animals received dobutamine (15 p,g * kg-' . min-' ) while the remaining 6, acting as time-controls, received saline at an identical infusion rate (Fig. 2) . One hour prior to the beginning of the control period (time zero), a heparin bolus (500 U/kg) was administered followed by a 250 U/kg/hr heparin infusion in both groups (Fig. 2) . Intralipid (0.3 ml kg-' min-' ) was also infused one hour prior to the control period in both groups to maintain plasma arterial FFA concentrations at -0.7-0.8 mM (Fig. 2) . This was done because dobutamine has previously been shown to increase FFA levels in swine [lo,1 11. Following the 30 min control period, dobutamine (15 kg * kg-' . min-'1 was infused through the jugular vein to increase myocardial workload in the dobutamine group, while saline was infused into the saline group (Fig. 2) .
Arterial and coronary venous blood was sampled at 5, 15, and 25 min during the control period and at 35,45, and 55 min during the treatment period. Each sample was analyzed separately for determination of myocardial glucose, FFA, and lactate extraction, then the 3 samples collected during each period were averaged to come up with a final value for each period (Table 3 ). Left ventricular peak systolic and end-diastolic pressure, peak rate of change in pressure (dp/dt), rate X pressure product, and heart rate were recorded immediately prior to each arterial and venous blood sample collection, and averaged over each period. Fluorescent microspheres (-5 million, 15 km diameter, Interactive Medical Technologies, Los Angeles, CA) were injected into the left atrium at the mid- Sixty minutes prior to time zero heparin and intralipid infusions were started into both dobutamine and saline groups. Time zero marked the beginning of the 30 min control period. This was followed by a 30 min treatment period which began at 30 min. During the treatment period, the dobutamine group (n= 6) received dobutamine (15 pg.kg-'.min-'1, while the sal me group (n = 6) received saline at an identical infusion rate. Arterial and coronary venous blood samples were drawn at 5, 15, and 25 min during the control period, and at 35.45, and 55 min during the treatment period. Needle biopsies were taken near the end of each oeriod and analyzed for CoA ester content. At the completion of the treatment period a drill biopsy was taken to de&nine ACC and AMPK activities.
point of each period (16 and 46 min, respectively), and an arterial reference withdrawal sample for the calculation of blood flow was withdrawn from the femoral artery as previously described [lo] . At the completion of each study, a transmural biopsy of the left anterior descending bed was taken for analysis of tissue microspheres using flow cytometry [ 101.
At the completion of both the control and treatment periods, a myocardial needle biopsy was collected from the left ventricle with a 14-gauge Trucut" biopsy needle (lo-20 mg), and immediately (3-S s) freeze-clamped in metal blocks pre-cooled in liquid nitrogen for analysis of tissue CoA esters. A larger drill biopsy (100-200 mg) was collected at the end of each study as previously described [ 121, and used for the determination of ACC and AMPK activities. All biopsies were stored at -70°C until subsequent analysis. Lidocaine (20 mg) was administered i.v. to prevent arrhythmias prior to collection of the biopsies.
Analytical methoa?

Blood analysis
Arterial and venous pH, pCO,, pOz, and hemoglobin concentration and saturation were determined as previously described [ 10,131. MVO, was calculated as the product of mean blood flow and the arterial-venous oxygen difference. Blood samples for glucose and lactate concentrations were deproteinized in ice-cold 1M perchloric acid (I:2 vol/vol), and analyzed using previously described enzymatic spectrophotometric methods [ 131. Plasma FFA's were measured using a commercial enzymatic spectrophotometric kit (Wake Chemicals, USA, Richmond, VA) [ 131.
Tissue CoA ester content
Acetyl CoA, malonyl CoA, and CoA were assayed using HPLC separation and UV detection as previously described [4] .
ACC and AMPK activity
Approximately 200 mg of frozen tissue was homogenized and extracted as previously described [14] . ACC activity was determined using the ['4Clbicarbonate fixation assay as previously described [14] . AMPK was assayed by following the incorporation of '*P into a synthetic peptide as previously described [14] .
Statis tics
Unpaired t-tests were used to compare the saline and dobutamine groups within each period. To compare the effects of the different treatments (saline vs. dobutamine), the mean differences from the control to the treatment period for each variable were calculated. The mean differences for each group were then compared using unpaired t-tests. This was done to account for any baseline differences between the two groups. All results are presented as means f s.e. Difference between means at the 0.05 level were considered significant.
Results
Hemodynamics
Hemodynamic values are listed in Table 1 . No significant differences were seen between the two groups during the control period. Heart rate, left ventricular peak systolic pressure, MVO, , left ventricular dp/dt, and rate X pressure product were all increased in the dobutamine group compared to the saline group during the treatment period. Following dobutamine treatment, all of these variables were significantly increased as compared to the control period. In contrast, there were no significant differences in the saline group during the treatment period compared to the control period. Significantly different from saline group, + significantly different from control period, P < 0.05.
Regional blood flow
Regional myocardial blood flow values are listed in Table 2 , and are similar to previously reported values [ lo,1 I]. Regional blood flow in the saline group was unchanged from the control to the treatment period. In the dobutamine group, subepicardial, midmyocardial, and subendocardial blood flow increased by 197, 219, and 262%, respectively, during the treatment period. Compared to the saline group, the dobutamine group exhibited significantly increased myocardial blood flow in all 3 regions. There was no evidence for subendocardial ischemia during control conditions or with dobutamine treatment. Significantly different from saline group, + significantly different from control period, P < 0.05. groups during the control period. FFA uptake increased significantly with dobutamine infusion (Fig. 3, Table 3 ). In addition, net lactate uptakes were significantly increased in the dobutamine group during the treatment period compared to the control period. Glucose uptake tended to be higher in the dobutamine group during the treatment period compared to the control period, but this increase was not statistically significant. The values for glucose, lactate and FFA uptake did not vary as a function of time during the control or the treatment periods.
3.4. CoA esters Dobutamine treatment resulted in a 55% decrease in malonyl CoA content (from 0.40 f 0.05 to 0.18 f 0.12 nmol/g wet wt; P < 0.051, which corresponded to an increase in FFA uptake (Fig. 3) . Acetyl CoA levels were not effected by treatment with dobutamine (1.26 f 0.25 and 1.30 f 0.52 nmol/g wt wt. for control and dobutamine periods, respectively). Neither malonyl CoA nor acetyl CoA was affected by treatment with saline (data not shown). The rate of fatty acid uptake was negatively correlated with myocardial malonyl CoA levels (r = -0.55; FPA uptake = -0.88x+0.61. higher in this study ( -700-l 800 pmol . min-' . mg protein-') compared to that in isolated rat hearts (400-800 pm01 . min -I * mg protein-' ) [14].
3.5. ACC and AMPK activity 4. Discussion ACC activity was measured in the absence and presence of 10 mM citrate, since citrate is a known allosteric activator of ACC. As expected, there was a significant increase in myocardial ACC activity in the presence of citrate in both groups (Fig. 4) . However, ACC activity was not significantly different from the treatment period to the control period in either group (Fig. 4) .
AMPK has been shown to phosphorylate ACC and inhibit its activity. The effects of dobutamine treatment on AMPK activity in the absence and presence of AMP are shown in Fig. 5 . As expected, the addition of AMP caused a significant increase in AMPK activity in both groups (Fig. 5) . However, AMPK activity was not significantly different between the two groups. AMPK activity values measured in the absence of AMP in this study were similar to values reported in isolated working rat hearts. ACC was isolated and the activity measured as described in the Methods section. ' Significantly different from ACC activity measured in the absence of 10 mM citrate, P < 0.05.
The purpose of this study was to determine if the increase in fatty acid uptake following dobutamine infusion is accompanied by a decrease in malonyl CoA levels in swine hearts. Dobutamine, a selective P-agonist, was used to induce an acute increase in myocardial workload in intact anesthetized swine. Malonyl CoA content was decreased by 55% and FPA uptake was increased by 210% with dobutamine treatment, while neither was affected by saline treatment (Fig. 3) . Thus, the results of this study show that the increased cardiac work following dobutamine infusion is accompanied by a decrease in malonyl CoA levels and an increase in fatty acid uptake; however, the decrease in malonyl CoA was not explained by direct phosphorylation and inhibition of ACC by AMPK, suggesting that the work-induced decrease in malonyl CoA we observed was not regulated via the protein phosphorylation cascade of ACC. In addition, we did not observe a decrease in acetyl CoA levels with increased work, suggesting that the substrate supply to ACC was not regulating malonyl CoA production under these conditions.
To our knowledge, this is the first study to measure myocardial ACC and AMPK activities in swine, and in any species under conditions of increased work. The lack of change in AMPK and ACC activities with the p-adrenoceptor agonist, dobutamine, suggests that these enzymes do not play a major role in the regulation of myocardial metabolism under these experimental conditions. This contrasts with the situation in the postischemic heart where AMPK activity is significantly increased, resulting in a dramatic drop in ACC activity and malonyl CoA levels [14] . The possibility exists that AMPK phosphorylation of ACC in the heart only occurs under conditions of severe metabolic stress. It is also possible that transient changes in ACC and/or AMPK activities occurred prior to tissue biopsy in this study.
In contrast to what we observed in the heart, Haystead and co-workers [El previously demonstrated inhibition of ACC in rat adipocytes by the P-agonist, isoproterenol, through stimulation of AMPK in vitro. The ability of a P-agonist to induce inhibition of ACC through stimulation of AMPK in isolated adipocytes and not the heart may be explained by the function of ACC in adipocytes. In addition to being a potent inhibitor of CPTl and hence fatty acid catabolism, malonyl CoA serves as the first step in fatty acid biosynthesis. In adipose tissue, the major role of ACC is in the de nouo synthesis of fatty acids. Thus, the ability to phosphorylate and inhibit ACC through stimulation of AMPK in adipocytes provides a mechanism whereby biosynthetic pathways are turned off under stressful cellular conditions in tissues actively undergoing de norm fatty acid synthesis. If this hypothesis is true, then inhibition of ACC in response to P-agonist in tissues not actively undergoing fatty acid biosynthesis, such as heart, would be far less important than in adipocytes which are actively synthesizing fatty acids. It is interesting that unlike adipose tissue, which expresses ACC 265, heart primarily expresses ACC,280 141. The differential expression of these two isoforms may partly account for the differences in the regulation of ACC by AMPK.
In this study we demonstrated no change in AMPK activity in response to dobutamine infusion in the pig heart. This suggests that the decrease in malonyl CoA with increased work is not due to phosphorylation of ACC by AMPK. Similar to other well-known phosphorylation cascade signaling mechanisms, AMPK is itself phosphorylated via AMPK kinase [8, 16, 17] . It is relevant to note, however, that AMPK activity measured in these pig hearts was very high compared to the activity reported in liver [8] . To date, no function of this AMPK in swine heart has been identified. It is possible that AMPK regulates fatty acid metabolism in swine heart under conditions of more severe stress.
Dobutamine treatment also resulted in a significant increase in net lactate uptake and an increase in glucose uptake (not statistically significant), which means that there was a greater flux through pyruvate dehydrogenase (PDH). Flux through PDH is regulated by the activition state of the enzyme, the concentration of pyruvate. and product inhibition by acetyl CoA and NADH [l&19]. We recently found that the PDH activation state is not increased with dobutamine stimulation in the same swine model (Hall JL, Stanley WC, McCormack JG, unpublished observation) even though lactate and glucose uptake are increased, suggesting that dobutamine increases flux through PDH by increasing pyruvate formation and/or by decreasing product inhibition on PDH.
An increase in cardiac work with dobutamine did not result in a decrease in acetyl CoA levels, which suggests that the reduction in malonyl CoA with increased work is not due to a decrease in the substrate for ACC. However, one must use caution in interpreting total tissue acetyl CoA levels. It may be that an increase in cardiac work results in an increase in the acetyl CoA concentration in the mite chondria and a concomitant decrease in the cytosolic level. As a result, the acetyl CoA supply to ACC may be decreased despite no measurable change in total tissue levels. Unfortunately, no good techniques are available to accurately measure cytosolic and mitochondrial acetyl CoA levels in the heart. Studies with dichloroacetate suggest that large increases in total acetyl CoA levels (by increasing the flux through pyruvate dehydrogenase) will increase malonyl CoA levels by increasing the acetyl CoA supply to cytosolic ACC 14,191. Another explanation for the reduction in malonyl CoA levels in dobutamine-treated hearts may be increased activity of malonyl CoA decarboxylase, the enzyme responsible for the degradation of malonyl CoA [20] . It is possible that malonyl CoA decarboxylase could be a key regulator of myocardial malonyl CoA levels. Malonyl CoA decarboxylase activity was not measured in the present investigation. Measurement of malonyl decarboxylase activity in whole tissue homogenate would not reflect cytosolic activity because most of the activity resides in the mitochondrial matrix, and thus is not available to regulate cytosolic levels of malonyl CoA (Kozak R, Lopaschuk, GD, unpublished observations). Additional investigation is needed before the role of malonyl decarboxylase in the regulation of cardiac malonyl CoA levels is understood.
Our values for myocardial malonyl CoA concentration are about 15-20% of those reported in isolated rat and rabbit hearts using the same HPLC method [3, 4, 14] . This difference appears to be due to lower ACC activity in swine heart. In the present investigation we found lower ACC activity in swine myocardium (0.3 and 0.43 nmol . min-' . mg protein-' in the absence and presence of 10 mM citrate, respectively) than in aerobic buffer-perfused rat hearts (m 9 and 18 nmol . min-' . mg protein-' [ 141). Thus one would expect the lower concentration of malonyl CoA that we observed in the myocardium of swine relative to the rat.
In conclusion, the results of this study show that the increased cardiac work following dobutamine infusion is accompanied by a decrease in malonyl CoA levels and an increase in fatty acid uptake. ACC and AMPK activities were unchanged with increased work, suggesting that the decrease in malonyl CoA is not regulated by phosphorylation and inhibition of ACC.
